Microsoft ties up with NVIDIA to drive healthcare innovation

According to a press release, this collaborative effort aims to amalgamate the scale and computing capabilities of Microsoft Azure with NVIDIA DGX Cloud and the NVIDIA Clara suite, facilitating accelerated innovation and enhanced patient care in healthcare and life sciences organisations globally.

Peter Durlach, Corporate Vice President of Health & Life Sciences at Microsoft, said of this collaboration, “Microsoft is building on its longstanding collaboration with NVIDIA to empower the healthcare and life sciences industry with the power of Azure and generative AI, helping unlock new horizons for clinical research, drug discovery, and patient care worldwide.”

According to the press release the collaboration opens doors for healthcare providers, pharmaceutical companies, biotechnology firms, and medical device developers to innovate rapidly across clinical research, drug discovery, and care delivery with enhanced efficiency and effectiveness.

Kimberly Powell, Vice President of Healthcare at NVIDIA, said, “The convergence of AI, cloud computing, and healthcare is set to transform patient care.”

Microsoft widens availability of its AI-powered cybersecurity assistant

One of the highlights of this collaboration is the acceleration of drug discovery through NVIDIA BioNeMo hosted on NVIDIA DGX Cloud, facilitated by Microsoft Azure. BioNeMo serves as a generative AI platform simplifying and expediting the training of models on proprietary data, consequently hastening AI-powered drug discovery processes. This advancement promises faster access to life-saving therapies for patients globally.

Moreover, the collaboration aims to enhance clinical research and care delivery by leveraging imaging-based AI diagnostic technology. The combination of Azure, NVIDIA MONAI (Medical open network for AI), and the Nuance Precision Imaging Network facilitates the development, validation, deployment, and evaluation of medical imaging AI models at scale.

This empowers developers to build highly performant medical imaging AI models while enabling healthcare providers to deploy a single platform for running a wide array of third-party AI models integrated into clinical workflows.

Flywheel, in collaboration with NVIDIA and researchers at the University of Wisconsin School of Medicine and Public Health, is spearheading efforts to revolutionise medical imaging research through AI technology. The initiative combines research insights, imaging data platforms, and NVIDIA MONAI microservices to enable automated anatomical study classifications, representing a significant leap toward AI-driven medical breakthroughs.

The collaboration between Microsoft, NVIDIA, and SOPHiA GENETICS aims to accelerate genomics analysis with the SOPHiA DDM Platform on Azure powered by NVIDIA Parabricks. This comprehensive solution streamlines whole-genome analytical processes, providing actionable insights for healthcare institutions worldwide.

Microsoft will also make a suite of NVIDIA healthcare microservices available on Azure AI. This initiative aims to optimise inference and fine-tuning, driving innovation and redefining patient care through collaborative efforts across disciplines.

Microsoft tailors AI for finance teams in specialised ‘Copilot’ strategy